1-6 of 6
Rebecca G Bagley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Ibrahim Aldoss, Ghayas C. Issa, James S. Blachly, Michael J. Thirman, Gabriel N Mannis, Martha L. Arellano, John F. DiPersio, Elie Traer, C. Michel Zwaan, Neerav Shukla, Branko Cuglievan, Carolyn S. Grove, Matthew Greenwood, Christine M. McMahon, Alexander E. Perl, Richard M. Stone, Cristina Papayannidis, David S. Dickens, Maël Heiblig, Andrius Žučenka, Pau Montesinos, Ioannis Mantzaris, Tibor Kovacsovics, Paul J. Shami, Li Yu, Rebecca G. Bagley, Nicole McNeer, Eytan M. Stein
Journal: Blood
Blood (2024) 144 (Supplement 1): 211.
https://doi.org/10.1182/blood-2024-194384
Published: 2024
Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Ibrahim Aldoss, Ghayas C. Issa, Michael Thirman, John DiPersio, Martha Arellano, James S. Blachly, Gabriel N. Mannis, Alexander Perl, David S. Dickens, Christine M. McMahon, Elie Traer, C. Michel Zwaan, Carolyn Grove, Richard Stone, Paul J. Shami, Ioannis Mantzaris, Matthew Greenwood, Neerav Shukla, Branko Cuglievan, Yu Gu, Rebecca G. Bagley, Kate Madigan, Soujanya Sunkaraneni, Huy Van Nguyen, Nicole McNeer, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 2): LBA-5.
https://doi.org/10.1182/blood-2023-192042
Published: 2023
Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Ibrahim Aldoss, Ghayas C. Issa, Michael J Thirman, John DiPersio, Martha Arellano, James S. Blachly, Gabriel Mannis, Alexander Perl, David Dickens, Christine M. McMahon, Elie Traer, C. Michel Zwaan, Carolyn Grove, Richard Stone, Paul J Shami, Ioannis Mantzaris, Matthew Greenwood, Neerav Shukla, Branko Cuglievan, Yu Gu, Rebecca G Bagley, Kate Madigan, Soujanya Sunkaraneni, Huy Van Nguyen, Nicole McNeer, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 2907.
https://doi.org/10.1182/blood-2023-189762
Published: 2023
Journal Articles

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

Ghayas C. Issa, Branko Cuglievan, Eytan Stein, Martha L. Arellano, Andrius Žucenka, Nandita Khera, Richard M. Stone, Michael J. Thirman, John F. DiPersio, Nicole Karras, Yu Gu, Rebecca G. Bagley, Galit Rosen, David Tamang, Kimberly Dishman, Sushama Scalera, Michael L. Meyers, Kate Madigan, Nicole McNeer, Ibrahim Aldoss
Journal: Blood
Blood (2022) 140 (Supplement 1): 914–916.
https://doi.org/10.1182/blood-2022-164600
Published: 2022
Journal Articles

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A -Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio, Branko Cuglievan, Richard M. Stone, Martha L. Arellano, Michael J. Thirman, Manish R. Patel, David Dickens, Shalini Shenoy, Neerav Shukla, Galit Rosen, Rebecca G. Bagley, Michael L. Meyers, Kate Madigan, Peter Ordentlich, Yu Gu, Steven Smith, Gerard M. McGeehan, Eytan Stein
Journal: Blood
Blood (2022) 140 (Supplement 1): 150–152.
https://doi.org/10.1182/blood-2022-164849
Published: 2022
Journal Articles

Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)

Eytan M. Stein, Ibrahim Aldoss, John F. DiPersio, Richard M. Stone, Martha L. Arellano, Galit Rosen, Michael L. Meyers, Yifan Huang, Steve Smith, Rebecca G. Bagley, Michael Thirman, Manish R. Patel, Ghayas C. Issa
Journal: Blood
Blood (2021) 138 (Supplement 1): 699.
https://doi.org/10.1182/blood-2021-146944
Published: 2021